I-Mab (IMAB)
| Market Cap | 257.61M |
| Revenue (ttm) | 18.23M |
| Net Income (ttm) | -343.57M |
| Shares Out | 83.10M |
| EPS (ttm) | -4.29 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 511,882 |
| Open | 3.21 |
| Previous Close | 3.23 |
| Day's Range | 3.05 - 3.28 |
| 52-Week Range | 3.05 - 21.44 |
| Beta | 1.02 |
| Analysts | Buy |
| Price Target | 38.10 (+1,129.03%) |
| Earnings Date | Mar 31, 2023 |
About IMAB
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 mo... [Read more]
Analyst Forecast
According to 17 analysts, the average rating for IMAB stock is "Buy." The 12-month stock price forecast is $38.1, which is an increase of 1,129.03% from the latest price.
News
I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023
GAITHERSBURG, Md. and SHANGHAI, China , March 20, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and com...
MSCI ESG Updated I-Mab to "A" Rating
GAITHERSBURG, MD. and SHANGHAI , March 7, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commerciali...
I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022
GAITHERSBURG, MD. and SHANGHAI , Nov. 3, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercializ...
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in I-Mab with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - October 10, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ...
Here's Why IMab Sponsored ADR (IMAB) is Poised for a Turnaround After Losing 26.8% in 4 Weeks
IMab Sponsored ADR (IMAB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in...
I-Mab Announces Poster Presentations of CD47 Antibody Lemzoparlimab and CD73 Antibody Uliledlimab at SITC 2022
GAITHERSBURG, MD. and SHANGHAI, China , Oct. 5, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and comme...
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in I-Mab with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - September 19, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of I-Mab - IMAB
New York, New York--(Newsfile Corp. - September 17, 2022) - Pomerantz LLP is investigating claims on behalf of investors of I-Mab ("I-Mab" or the "Company") (NASDAQ: IMAB). Such investors are advised ...
I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome
GAITHERSBURG, Md. and SHANGHAI , Sept, 13, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercial...
I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022
Lemzoparlimab combined with AZA showed encouraging clinical response in higher-risk MDS patients For patients received initial dose over 3 months, the ORR is 80.6% and for patients received initial do...
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in I-Mab with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - September 7, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ...
I-Mab Announces Oral Presentation of Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022
Abstract summarizing lemzoparlimab Phase 2 data selected for proffered paper presentation on September 10 Investor conference call scheduled at 8:00 a.m. ET (English) on September 12 GAITHERSBURG, Md.
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in I-Mab with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - September 5, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ...
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in I-Mab with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - September 2, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
New York, New York--(Newsfile Corp. - September 1, 2022) - Pomerantz LLP is investigating claims on behalf of investors of I-Mab (NASDAQ: IMAB) ("I-Mab" or the "Company"). Such investors are advised t...
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2022
Seven key clinical milestones achieved year-to-date, including positive data readouts for lemzoparlimab, uliledlimab, and TJ-CD4B Lemzoparlimab is on track for Phase 3 study for 1L MDS Amendment to th...
I-Mab Announces Share Purchase Plans by the Company and the Senior Management
GAITHERSBURG, Md. and SHANGHAI , Aug. 23, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and ...
I-Mab to Report Business and Corporate Updates and Financial Results for the Six Months Ended June 30, 2022 on August 30, 2022
- M ajor updates will focus on global clinical development of core assets, upcoming milestones and financial results - The Company will update on potential implementation of a comprehensive share pu...
I-Mab (IMAB) Down After Partner AbbVie Revises Partnership Deal
I-Mab's (IMAB) partner AbbVie decides to stop early-stage development of an anti-CD47 antibody therapy targeting multiple cancer indications. IMAB intends to support the candidate's development.
I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1BB Bispecific Antibody TJ-CD4B in Solid Tumors in China
GAITHERSBURG, Md. and SHANGHAI , July 22, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commerciali...
I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022
GAITHERSBURG, Md. and SHANGHAI , July 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commerciali...
I-Mab to Host 2022 R&D Day
GAITHERSBURG, MD. and SHANGHAI , July 6, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and c...
I-Mab Receives Top Rankings in Five Categories by Institutional Investor
GAITHERSBURG, Md. and SHANGHAI , June 23, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and ...
I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210
SHANGHAI and GAITHERSBURG, Md. , June 15, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commerciali...
Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)
SEOUL, South Korea--(BUSINESS WIRE)--Genexine (KOSDAQ: 095700) a publicly traded, clinical stage biopharmaceutical company committed to the discovery and development of novel biologics for the treatme...